Activation of the cytotoxic programs in NK cells and CD8+ T cells is key for cancer immunotherapy, and consequently early studies provided compelling evidence that IL-21 is a promising immunotherapeutic agent for this disease56. This evidence concerns the gene CD8A and cancer.